Precision Optics Corporation, Inc. — FY2018 Form 10-K
Reporting period: Fiscal year ended June 30, 2018, compared with fiscal 2017. Although the request metadata says “2017 Q4,” this filing reports fiscal 2018 results; it is an annual report, not a quarterly filing.
Business context
The company designs and manufactures optical instruments, principally medical endoscopes, endocouplers, imaging and illumination systems, and related components. About 17% of fiscal 2018 revenue came from military and industrial products. Its growth strategy centers on customer engineering projects and production using Microprecision optics, micro medical cameras, and 3D endoscopy technology.
Financial results and liquidity
| Metric | FY2018 | FY2017 |
|---|---|---|
| Revenue | $4,038,048 | $3,154,547 |
| Gross profit | $1,481,918 | $773,724 |
| Gross margin | 36.7% | 24.5% |
| Research and development expense | $456,377 | $464,162 |
| Selling, general and administrative expense | $1,374,160 | $1,313,478 |
| Operating loss | $348,619 | $1,002,401 |
| Net loss | $351,390 | $1,006,457 |
| Net cash from (used in) operating activities | $100,657 | $(667,434) |
- Revenue rose 28.0%; production revenue increased 54.8%, while engineering-services revenue decreased 6.7%.
- Management attributed improved gross margin to higher sales, production efficiencies, better fixed-cost absorption, and engineering work performed under customer contracts.
- At June 30, 2018, cash was $402,738, accounts receivable were $796,923, inventory was $1,144,068, and current liabilities were $1,932,844. Working capital was $481,876.
- Current liabilities included $857,842 of customer advances against open purchase orders. The company reported $23,563 in capital lease obligations, including current and long-term portions; no other material borrowing is identified in the filing.
- Operating cash flow was positive despite the net loss, supported in part by $677,705 in customer advances and noncash adjustments. Cash increased by $284,333 during the year; financing activities provided $205,313, including stock-placement proceeds.
- Accounts receivable included a $227,500 specific reserve for one customer’s unpaid design-services balance; the total allowance for doubtful accounts was $232,500.
Changes, outlook, and risks
- Three significant customer projects transitioned from engineering to production orders during FY2018. Management cited an ongoing pipeline of customer development projects and expects additional projects may move into production, but provided no quantified revenue or earnings guidance.
- Customer concentration remains material: the two largest customers generated 16% and 14% of FY2018 revenue. Four customers represented 64% of year-end receivables.
- The company reported recurring losses and stated it may need additional financing if sales and cash flow are inadequate. Further equity financing could dilute shareholders; debt financing may be unavailable or restrictive.
- Fixed-price purchase orders represented approximately 25%–50% of revenue in recent years and may be unprofitable if costs are underestimated. Revenue also depends on customers continuing to use the company as a supplier.
- Other stated risks include dependence on a small number of key personnel, FDA and other regulatory requirements, limited sources for specialized components and services, competition from larger companies, and potential inventory valuation or obsolescence issues.
- Management reported two material weaknesses in internal control over financial reporting: insufficient segregation of accounting duties and inventory valuation controls. Management said review procedures were operating, but concluded controls were not effective at June 30, 2018. The auditor issued an unqualified opinion on the financial statements but did not opine on internal-control effectiveness.
- After year-end, the company approved new CEO and CFO compensation arrangements, including share and option awards. The CEO agreement includes 300,000 shares and options for 350,000 shares; the CFO agreement includes options for 100,000 shares, subject to stated vesting terms.
- The filing reports no material pending or threatened litigation and no off-balance-sheet arrangements. The main Gardner facility is leased month-to-month from a company owned by the former CEO; rent was $108,000 in each of FY2018 and FY2017.
Important facts for investors to verify
- Reconcile receivables: the audited balance sheet reports $796,923, while one risk-factor passage states $769,923. Confirm the correct figure and assess collectability of the reserved customer balance.
- Track whether customer advances convert into timely, profitable shipments, and whether the production pipeline yields repeat orders and sustained positive operating cash flow.
- Monitor cash needs, working capital, financing plans, and potential dilution from future securities issuances and outstanding equity awards.
- Assess remediation of the disclosed accounting and inventory-control material weaknesses and review subsequent filings for any changes.
- Verify the effects of customer concentration, fixed-price contract performance, component-supplier availability, and regulatory requirements on margins and delivery.